These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 21699856

  • 1. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
    Nof E, Belhassen B, Arad M, Bhuiyan ZA, Antzelevitch C, Rosso R, Fogelman R, Luria D, El-Ani D, Mannens MM, Viskin S, Eldar M, Wilde AA, Glikson M.
    Heart Rhythm; 2011 Oct; 8(10):1546-52. PubMed ID: 21699856
    [Abstract] [Full Text] [Related]

  • 2. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
    Nozaki Y, Kato Y, Uike K, Yamamura K, Kikuchi M, Yasuda M, Ohno S, Horie M, Murayama T, Kurebayashi N, Horigome H.
    Circ J; 2020 Jan 24; 84(2):226-234. PubMed ID: 31875585
    [Abstract] [Full Text] [Related]

  • 3. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
    Seidlmayer LK, Riediger F, Pagonas N, Nordbeck P, Ritter O, Sasko B.
    J Med Case Rep; 2018 Oct 09; 12(1):298. PubMed ID: 30296944
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A novel cardiac ryanodine receptor gene (RyR2) mutation in an athlete with aborted sudden cardiac death: a case of adult-onset catecholaminergic polymorphic ventricular tachycardia.
    Arakawa J, Hamabe A, Aiba T, Nagai T, Yoshida M, Touya T, Ishigami N, Hisadome H, Katsushika S, Tabata H, Miyamoto Y, Shimizu W.
    Heart Vessels; 2015 Nov 09; 30(6):835-40. PubMed ID: 25092222
    [Abstract] [Full Text] [Related]

  • 6. Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation.
    Itoh H, Murayama T, Kurebayashi N, Ohno S, Kobayashi T, Fujii Y, Watanabe M, Ogawa H, Anzai T, Horie M.
    J Electrocardiol; 2021 Nov 09; 69():111-118. PubMed ID: 34656916
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M, Yin H, Knollmann BC.
    Circ Arrhythm Electrophysiol; 2011 Apr 09; 4(2):128-35. PubMed ID: 21270101
    [Abstract] [Full Text] [Related]

  • 8. A novel variant in RyR2 causes familiar catecholaminergic polymorphic ventricular tachycardia.
    Bosch C, Campuzano O, Sarquella-Brugada G, Cesar S, Perez-Serra A, Coll M, Mademont I, Mates J, Del Olmo B, Iglesias A, Brugada J, Petersen V, Brugada R.
    Forensic Sci Int; 2017 Jan 09; 270():173-177. PubMed ID: 27988446
    [Abstract] [Full Text] [Related]

  • 9. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
    Wangüemert F, Bosch Calero C, Pérez C, Campuzano O, Beltran-Alvarez P, Scornik FS, Iglesias A, Berne P, Allegue C, Ruiz Hernandez PM, Brugada J, Pérez GJ, Brugada R.
    Heart Rhythm; 2015 Jul 09; 12(7):1636-43. PubMed ID: 25814417
    [Abstract] [Full Text] [Related]

  • 10. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
    Watanabe H, Knollmann BC.
    J Electrocardiol; 2011 Jul 09; 44(6):650-5. PubMed ID: 21872879
    [Abstract] [Full Text] [Related]

  • 11. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C, Dechering DG, Reinke F, Muszynski A, Zellerhoff S, Bittner A, Köbe J, Wasmer K, Schulze-Bahr E, Mönnig G, Kotthoff S, Eckardt L.
    Europace; 2011 Jun 09; 13(6):897-901. PubMed ID: 21292648
    [Abstract] [Full Text] [Related]

  • 12. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J, Xie W, Betzenhauser M, Reiken S, Chen BX, Wronska A, Marks AR.
    Circ Res; 2012 Aug 31; 111(6):708-17. PubMed ID: 22828895
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Diverse Phenotypic Manifestations in a Family with a Novel RYR2 E4107A Variant.
    Hasegawa H, Tamura S, Nakajima T, Kawabata-Iwakawa R, Kobari T, Matsumoto N, Sano Y, Nishiyama M, Kurabayashi M, Kaneko Y, Nakatani Y, Ishii H.
    Int Heart J; 2024 Aug 31; 65(3):580-585. PubMed ID: 38825499
    [Abstract] [Full Text] [Related]

  • 15. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
    Wangüemert Pérez F, Hernández Afonso JS, Groba Marco MDV, Caballero Dorta E, Álvarez Acosta L, Campuzano Larrea O, Pérez G, Brugada Terradellas J, Brugada Terradellas R.
    Rev Esp Cardiol (Engl Ed); 2018 Mar 31; 71(3):185-191. PubMed ID: 28789916
    [Abstract] [Full Text] [Related]

  • 16. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
    Duan H, Lu Y, Yan S, Qiao L, Hua Y, Li Y, Zhou K, Wang C.
    Medicine (Baltimore); 2018 Apr 31; 97(16):e0368. PubMed ID: 29668588
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing.
    Tester DJ, Kopplin LJ, Will ML, Ackerman MJ.
    Heart Rhythm; 2005 Oct 31; 2(10):1099-105. PubMed ID: 16188589
    [Abstract] [Full Text] [Related]

  • 19. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A, Marai I, Suleiman M, Blich M, Lorber A, Gepstein L, Boulos M.
    Heart Rhythm; 2013 Nov 31; 10(11):1671-5. PubMed ID: 23954267
    [Abstract] [Full Text] [Related]

  • 20. Search for cardiac calcium cycling gene mutations in familial ventricular arrhythmias resembling catecholaminergic polymorphic ventricular tachycardia.
    Marjamaa A, Laitinen-Forsblom P, Lahtinen AM, Viitasalo M, Toivonen L, Kontula K, Swan H.
    BMC Med Genet; 2009 Feb 12; 10():12. PubMed ID: 19216760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.